A5010580951- Neurotransmitter Receptor Influence on Behavior
- Circadian rhythm and melatonin
- Neuroscience and Neuropharmacology Research
- Cannabis and Cannabinoid Research
- Bipolar Disorder and Treatment
- Psychedelics and Drug Studies
- Sleep and Wakefulness Research
- Tryptophan and brain disorders
- Receptor Mechanisms and Signaling
- Treatment of Major Depression
- Neuroendocrine regulation and behavior
- Pain Mechanisms and Treatments
- Sleep and related disorders
- Schizophrenia research and treatment
- Neuropeptides and Animal Physiology
- Stress Responses and Cortisol
- Biochemical Analysis and Sensing Techniques
- Child and Adolescent Psychosocial and Emotional Development
- Chemical synthesis and alkaloids
- Psychopathy, Forensic Psychiatry, Sexual Offending
- Electroconvulsive Therapy Studies
- Pharmacological Effects and Toxicity Studies
- Information Science and Libraries
- Free Radicals and Antioxidants
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
McGill University
2016-2025
McGill University Health Centre
2016-2025
Edwards (United Kingdom)
2025
Instituto Federal do Espírito Santo
2024
University of Cagliari
2001-2023
Carleton University
2021
Instituto de Formación y Estudios Sociales
2019
Vita-Salute San Raffaele University
2018
GTx (United States)
2017
Winthrop-University Hospital
2016
Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability this drug prevent its therapeutic application. The active constituent cannabis, Δ 9 -tetrahydrocannabinol, acts by binding brain CB 1 cannabinoid receptors, but an alternative approach might develop agents amplify actions endogenous cannabinoids blocking their deactivation. Here, we show URB597, a selective inhibitor enzyme fatty-acid amide hydrolase,...
Abstract Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis interacts with serotonin (5-HT) 1A receptor, may possess analgesic and anxiolytic effects. However, its effects on 5-HT neuronal activity, as well impact models neuropathic pain are unknown. First, using in vivo single-unit extracellular recordings rats, we demonstrated acute intravenous (i.v.) increasing doses CBD (0.1-1.0 mg/kg) decreased firing rate neurons dorsal raphe nucleus, which...
Preclinical and clinical studies show that cannabis modulates mood possesses antidepressant-like properties, mediated by the agonistic activity of cannabinoids on central CB 1 receptors (CB Rs). The action R agonists serotonin (5-HT) system, major transmitter system involved in control implicated mechanism antidepressants, remains however poorly understood. In this study, we demonstrated that, at low doses, agonist WIN55,212-2 [...
Significance Social behavior (SB) is a fundamental hallmark of human interaction. Repeated administration low doses the 5-HT 2A agonist lysergic acid diethylamide (LSD) in mice enhances SB by potentiating and AMPA receptor neurotransmission mPFC via an increasing phosphorylation mTORC1, protein involved modulation SB. Moreover, inactivation glutamate impairs nullifies prosocial effects LSD. Finally, LSD requires integrity mTORC1 excitatory glutamatergic, but not inhibitory neurons, to...
Alterations in serotonin (5-hydroxytriptamine, 5-HT), norepinephrine, and gamma-aminobutyric acid have been linked to the pathophysiology of anxiety depression, medications that modulate these neurotransmitters are widely used treat mood disorders. Recently, neuropeptide substance P (SP) its receptor, neurokinin 1 receptor (NK1R), proposed as possible targets for new antidepressant anxiolytic therapies. However, animal human studies so far failed provide a clear consensus on role SP...
Abstract The involvement of melatonin in mammalian brain pathophysiology has received growing interest, but information about the anatomical distribution its two G‐protein‐coupled receptors, MT 1 and 2 , remains elusive. In this study, using specific antibodies, we examined precise both receptors immunoreactivity across adult rat light, confocal, electron microscopy. Our results demonstrate a selective localization on neuronal cell bodies dendrites numerous regions telencephalon,...
Current antidepressant treatments are inadequate for many individuals, and when they effective, require several weeks of administration before a therapeutic effect can be observed. Improving the treatment depression is challenging. Recently, two-pore domain potassium channel TREK-1 has been identified as new target in depression, its antagonists might become effective antidepressants. In mice, deletion gene results depression-resistant phenotype that mimics treatments. Here, we validate mice...
Melatonin activates two brain G-protein coupled receptors, MT(1) and MT(2), whose differential roles in the sleep-wake cycle remain to be defined. The novel MT(2) receptor partial agonist, N-{2-[(3-methoxyphenyl) phenylamino] ethyl} acetamide (UCM765), is here shown selectively promote non-rapid eye movement sleep (NREMS) rats mice. enhancement of NREMS by UCM765 nullified pharmacological blockade or genetic deletion receptors. but not MT(1), knock-out mice show a decrease compared wild...